Published in P T on March 01, 2013
Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99
Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50
Apixaban in patients with atrial fibrillation. N Engl J Med (2011) 9.97
Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation (2011) 6.47
Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet (1993) 5.77
Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost (2010) 4.45
Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 4.01
Translating the results of randomized trials into clinical practice: the challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation. Stroke (2006) 3.49
Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation (2011) 2.80
Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest (2006) 2.79
American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation (2003) 2.52
Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care (2009) 2.36
Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol (2010) 1.98
Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. J Am Coll Cardiol (2005) 1.97
Preventing stroke in patients with atrial fibrillation. JAMA (1999) 1.22
New oral anticoagulants in atrial fibrillation. Eur Heart J (2007) 1.14
Bleeding in patients using new anticoagulants or antiplatelet agents: risk factors and management. Neth J Med (2010) 1.06
Economic burden and cost determinants of deep vein thrombosis during 2 years following diagnosis: a prospective evaluation. J Thromb Haemost (2011) 1.06
Managing bleeding in anticoagulated patients with a focus on novel therapeutic agents. J Thromb Haemost (2009) 1.05
New antithrombotics for atrial fibrillation. Cardiovasc Ther (2010) 0.94
Warfarin therapy: influence of pharmacogenetic and environmental factors on the anticoagulant response to warfarin. Vitam Horm (2008) 0.83
Recombinant activated factor VII use in the emergency department. Emerg Med J (2008) 0.81
D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study. Ann Intern Med (2015) 2.63
Extensive prolongation of aPTT with argatroban in an elderly patient with improving renal function, normal hepatic enzymes, and metastatic lung cancer. Ann Pharmacother (2005) 1.40
The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. Br J Haematol (2011) 1.24
Factor XI deficiency and obstetrical anesthesia. Anesth Analg (2009) 1.03
Dabigatran: a review of clinical and pharmacoeconomic evidence. Crit Pathw Cardiol (2011) 0.84
New oral anticoagulants and the cancer patient. Oncologist (2013) 0.83
Clinical problem-solving. A bloody mystery. N Engl J Med (2009) 0.81
Case 155: Lane-Hamilton syndrome. Radiology (2010) 0.80
Extended treatment of venous thromboembolism. N Engl J Med (2013) 0.79
Comparing clinicians' use of an anticoagulation management service and usual care in ambulatory oncology. J Oncol Pharm Pract (2012) 0.77
Anesthetic management of seven deliveries in three sisters with the May-Hegglin anomaly. Anesth Analg (2009) 0.77
Prophylaxis against venous thromboembolism in patients with cancer. N Engl J Med (2014) 0.77
Clevidipine: a short-acting intravenous dihydropyridine calcium channel blocker for the management of hypertension. Pharmacotherapy (2010) 0.77
Management of inherited thrombophilia in pregnancy. Curr Opin Endocrinol Diabetes Obes (2009) 0.76
Benefits of CPOE. Am J Health Syst Pharm (2004) 0.75
Dabigatran excess: case report and review of the literature. Cardiol Ther (2013) 0.75
Treating venous thromboembolism in pregnancy. Hematol Oncol Clin North Am (2011) 0.75
Clinical JAK2V617F mutation testing: Limited utility for general hospital patients with venous and arterial thromboses in common locations. Am J Hematol (2008) 0.75
Regulatory, legislative, and policy updates with anticoagulant use. J Thromb Thrombolysis (2015) 0.75
Idarucizumab (Praxbind) Formulary Review. Crit Pathw Cardiol (2016) 0.75
Implementation of a Hemostatic and Antithrombotic Stewardship program. J Thromb Thrombolysis (2015) 0.75
Interactive medical case. A bloody mystery. N Engl J Med (2009) 0.75
Venous thromboembolism overview. Hematol Oncol Clin North Am (2012) 0.75